
Oncology
Dostarlimab Offers Treatment-Only Path in Rectal Cancer
Accelerated approval makes dostarlimab an initial option for previously untreated stage II or III MSI-H/dMMR rectal cancer, with the possibility of avoiding chemotherapy, radiation and surgery.
Rayan Salih · October 26, 2026 · 6 min

